

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

## **VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE**

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company that it intends to repurchase H shares of the Company (the “**H Shares**”) in the open market from time to time pursuant to the repurchase mandate granted at the annual general meeting of the Company held on May 28, 2026 and, where applicable, any future general mandate to repurchase H Shares as approved by the shareholders of the Company (the “**Shareholders**”) at the general meeting of the Company from time to time (the “**Repurchase Mandate**”).

The board of directors of the Company (the “**Board**”) considers the current trading price is at the level which significantly undervalues the Company’s intrinsic value, business prospects, or the recent business achievement. The Board believes that conducting share repurchases in the present conditions will demonstrate the Company’s confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to the Shareholders. The Company may make further repurchases according to market conditions, but in any case, subject to the availability of the then applicable Repurchase Mandate as part of its ongoing commitment to maximizing shareholder value.

The Company will conduct the share repurchases in compliance with the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Pursuant to Rule 10.06(2)(e) of the Listing Rules, an issuer shall not purchase its shares on the Stock Exchange at any time after inside information has come to its knowledge until the information is made publicly available. In particular, during the period of 30 days immediately preceding the earlier of (i) the date of the board meeting for the approval of the issuer’s results for any year, half-year, quarterly or any other interim period; and (ii) the deadline for the issuer to announce its results for any year or half-year under the Listing Rules, or quarterly or any other interim period, and ending on the date of the results announcement, the issuer shall not purchase its shares on the Stock Exchange, unless the circumstances are exceptional.

The Company will conduct the share repurchases in compliance with the articles of association of the Company, the Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs and all applicable laws and regulations to which the Company is subject.

The Company will subsequently cancel, hold in treasury, sell or transfer the repurchased H Shares, if any, as deemed appropriate by the Board.

**Shareholders and potential investors should note that any repurchase may be done subject to market conditions and at the Board’s absolute discretion. There is no assurance of the timing, quantity or price of any repurchase. Shareholders and potential investors should therefore exercise caution when dealing in the shares of the Company.**

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
宜明昂科生物醫藥技術（上海）股份有限公司  
**Tian Wenzhi**  
*Chairman and Executive Director*

Shanghai, the PRC, June 8, 2026

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song, Ms. Guan Mei and Mr. Zhang Ruliang as executive Directors; (ii) Dr. Xu Cong and Ms. Fu Dawei as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*